ZTI biosciences

ZTI Biosciences is a company that develops next-generation radiopharmaceuticals targeting difficult-to-treat solid tumors by integrating nanotechnology and biotechnology. Through its proprietary 'TeracARRIER' platform, it aims to improve treatment efficacy and minimize side effects by delivering radioactive isotopes directly to cancer cells using nanoparticles.